AveXis (NASDAQ: AVXS) and Spring Bank Pharmaceuticals (NASDAQ:SBPH) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation.

Risk & Volatility

AveXis has a beta of 3.05, meaning that its stock price is 205% more volatile than the S&P 500. Comparatively, Spring Bank Pharmaceuticals has a beta of 2.98, meaning that its stock price is 198% more volatile than the S&P 500.

Institutional and Insider Ownership

94.7% of AveXis shares are held by institutional investors. Comparatively, 28.3% of Spring Bank Pharmaceuticals shares are held by institutional investors. 18.6% of AveXis shares are held by insiders. Comparatively, 17.6% of Spring Bank Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.


This table compares AveXis and Spring Bank Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AveXis N/A -45.63% -42.21%
Spring Bank Pharmaceuticals N/A -86.83% -58.60%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for AveXis and Spring Bank Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AveXis 2 2 12 0 2.63
Spring Bank Pharmaceuticals 0 1 3 0 2.75

AveXis presently has a consensus target price of $103.80, indicating a potential upside of 4.56%. Spring Bank Pharmaceuticals has a consensus target price of $26.33, indicating a potential upside of 75.56%. Given Spring Bank Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Spring Bank Pharmaceuticals is more favorable than AveXis.

Earnings & Valuation

This table compares AveXis and Spring Bank Pharmaceuticals’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
AveXis N/A N/A -$134.28 million ($4.93) -20.14
Spring Bank Pharmaceuticals N/A N/A -$18.18 million ($2.43) -6.17

AveXis is trading at a lower price-to-earnings ratio than Spring Bank Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.


AveXis beats Spring Bank Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

About AveXis

AveXis, Inc. is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration. The survival motor neuron (SMN) is a protein for normal motor neuron signaling and function. Patients with SMA Type 1 either have experienced a deletion of their SMN1 genes, which prevents them from producing adequate levels of functional SMN protein, or carry a mutation in their SMN1 gene. AVXS-101 is designed to deliver a functional human SMN gene into the nuclei of motor neurons that then generates an increase in SMN protein levels.

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases. The Company’s SB 9200 selectively activates within infected cells the cellular proteins retinoic acid-inducible gene 1 (RIG-I) and nucleotide-binding oligomerization domain-containing protein 2 (NOD2) to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. The Company is also developing a second SMNH product candidate, SB 11285, as an immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of INterferon Genes (STING) pathway. The Company focuses on developing SB 9200 for the treatment of chronic hepatitis B virus (HBV).

Receive News & Stock Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related stocks with our FREE daily email newsletter.